Alpha Cognition Outlines 2026 Strategic Priorities After 2025 Commercial Momentum

Alpha Cognition provided a corporate update highlighting its 2026 strategic priorities, including expanding the prescriber base for its Alzheimer’s treatment ZUNVEYL, advancing multiple real-world and clinical studies, and broadening payor coverage and international approvals to support growth. The company also summarized its 2025 commercial execution milestones, such as licensing agreements, patent protection, capital raises, and initial market uptake, aimed at positioning it for operating profitability in 2027.

Learn More